NCT07035990View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Cystic Fibrosis (CF)
Interventions
DRUG

SION-451

"* Pharmaceutical form: tablet~* Route of administration: oral"

DRUG

SION-2222

"* Pharmaceutical form: capsule~* Route of administration: oral"

DRUG

SION-109

"* Pharmaceutical form: tablet~* Route of administration: oral"

DRUG

Placebo SION-451

Placebo matched to SION-451

DRUG

Placebo SION-2222

Placebo matched to SION-2222

DRUG

Placebo SION-109

Placebo matched to SION-109

Trial Locations (2)

3004

RECRUITING

Nucleus Network, Melbourne

4006

RECRUITING

Nucleus Network, Brisbane

All Listed Sponsors
lead

Sionna Therapeutics Inc.

INDUSTRY